Anavex Life Sciences Corp.
AVXL
$4.20
-$0.06-1.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -42.29% | -18.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.69% | -24.43% | |||
| Operating Income | 37.69% | 24.43% | |||
| Income Before Tax | 42.37% | 25.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.19% | 25.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 42.19% | 25.79% | |||
| EBIT | 37.69% | 24.43% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 44.23% | 26.24% | |||
| Normalized Basic EPS | 44.34% | 26.21% | |||
| EPS Diluted | 44.23% | 26.24% | |||
| Normalized Diluted EPS | 44.34% | 26.21% | |||
| Average Basic Shares Outstanding | 3.65% | 0.60% | |||
| Average Diluted Shares Outstanding | 3.65% | 0.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||